John Johnson Buys Shares of Axogen, Inc. (AXGN)

John Johnson recently bought 4,392 shares of Axogen, Inc. (NasdaqCM: AXGN) on June 24, 2026. The shares were trading near $44.49 on Saturday, reflecting his confidence in the company.

Insider Buying and Selling at Axogen, Inc.

Several insiders, including John Johnson, purchased shares of Axogen, Inc. on June 24, 2026. Each insider, including Kathy Johnson Weiler, Joseph Tyndall, Paul Thomas, Amy McBride Wendell, and William Burke, bought 4,392 shares, except for Paul Thomas, who acquired 5,579 shares. These transactions were not part of any pre-planned trading scheme.

Other Institutional Activity in Axogen, Inc.

FIRST LIGHT ASSET MANAGEMENT, LLC decreased its holdings by 1,230,558 shares, ending with 4,002,768 shares valued at approximately $132.6 million. BLACKROCK, INC. added 151,414 shares, bringing its total to 3,870,851 shares worth around $128.2 million. MORGAN STANLEY increased its position by 536,112 shares, totaling 3,122,982 shares valued at $103.5 million. VANGUARD CAPITAL MANAGEMENT LLC opened a new position with 2,291,563 shares valued at about $75.9 million. Meanwhile, ARROWMARK COLORADO HOLDINGS LLC grew its stake by 441,157 shares to 1,915,439 shares, worth approximately $63.5 million, and WASATCH ADVISORS LP more than doubled its position, adding 933,778 shares to hold 1,857,350 shares valued at $61.5 million.

Axogen, Inc. Stock Down 12.7%

Shares of Axogen, Inc. traded near $44.49 on Saturday. The company has a market capitalization of approximately $2.37 billion and a forward P/E ratio of 61.1. Its beta is 1.118, indicating moderate volatility. The stock's 52-week range is between $10.20 and $46.00, with a 50-day moving average of $41.31 and a 200-day moving average of $30.96. Axogen maintains a solid financial position with a current ratio of 7.10 and a quick ratio of 4.99, alongside a low debt-to-equity ratio of 8.43.

Recent Earnings

Axogen, Inc. reported revenue of $238.1 million, reflecting a growth rate of 26.6%. Despite the revenue increase, the company posted a negative net margin of 13.21% and a return on equity of -17.96%, indicating ongoing challenges in profitability. The next earnings report is scheduled for August 4, 2026.

Analysts Set New Price Targets

On April 29, 2026, Canaccord Genuity, Citizens, and Wells Fargo maintained their 'buy' ratings on Axogen, Inc. with price targets of $50.00 and $48.00, respectively. HC Wainwright & Co. also maintained a 'buy' rating with a $50.00 target. The consensus among analysts is a 'buy' rating, with an average price target of $50.78 based on nine opinions.

About Axogen, Inc.

Axogen, Inc. is a healthcare company based in Alachua, Florida, specializing in medical devices for peripheral nerve regeneration and repair. Led by CEO Ms. Lindsey Hartley, the company offers products like the Avance Nerve Graft and Axoguard Nerve Connector, serving hospitals and surgery centers worldwide. Axogen employs 622 people and continues to innovate in the field of nerve repair technologies.

Bottom Line

Insider buying at Axogen, Inc. suggests confidence from within the company. With a solid market position and upcoming earnings, investors are closely watching Axogen's performance. Keep in mind that insider transactions, like the recent purchases by John Johnson and others, are often disclosed after the fact, so they provide a historical view rather than a current snapshot.